{"id":"W4380080925","doi":"10.1002/hon.3163_81","title":"ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"Seoul National University; Seoul National University Hospital; Institut National de la Santé et de la Recherche Médicale; Regeneron Pharmaceuticals; Cleveland Clinic","keywords":"Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Rituximab; Refractory (planetary science); Oncology; International Prognostic Index; Clinical endpoint; Progression-free survival; Neutropenia; Salvage therapy; Gastroenterology; Surgery; Chemotherapy; Lymphoma; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005117685,0.0004484725,0.001467079,0.0004723454,0.0001300629,0.00094755,0.0006487178,0.0003209659,0.001492825],"category_scores_gemma":[0.003010734,0.000232873,0.002076029,0.0009965826,0.0002390699,0.0005728403,0.0004030137,0.0009331524,0.0001732836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006021024,"about_ca_system_score_gemma":0.0006277867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189202,"about_ca_topic_score_gemma":0.003735032,"domain_scores_codex":[0.9984457,0.0008873996,0.0001444339,0.0001799179,0.0002565689,0.00008599918],"domain_scores_gemma":[0.9976556,0.000954225,0.0008269975,0.0002060877,0.0001715002,0.000185461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3326929,0.001195973,0.2381345,0.005392321,0.05111958,0.0003351745,0.0003670605,0.004416569,0.01000863,0.0007068095,0.01140874,0.3442217],"study_design_scores_gemma":[0.1222999,0.03928623,0.7120861,0.0008902446,0.08062315,0.001426025,0.0001883691,0.003847256,0.002799708,0.0007947675,0.03563562,0.0001226566],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9269649,0.06220238,0.0007091134,0.0008495233,0.0001011863,0.000411763,0.004873375,0.00005032265,0.003837479],"genre_scores_gemma":[0.9806955,0.01182497,0.001025064,0.0006912288,0.0002326848,0.0002193144,0.004691915,0.00002151579,0.0005977877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005117685,"threshold_uncertainty_score":0.02706522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03278476210436797,"score_gpt":0.3275913327918503,"score_spread":0.2948065706874823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}